CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.Bruce Ruggeri, Craig A. Dionne, Роберто Пили et al.|PubMed|2003Cited by 124
A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055Diane E. Gingrich, Robert L. Hudkins, Jeffry L. Vaught et al.|Journal of Medicinal Chemistry|2003Cited by 74
Discovery and Characterization of 6-{4-[3-(<i>R</i>)-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2<i>H</i>-pyridazin-3-one (CEP-26401, Irdabisant): A Potent, Selective Histamine H<sub>3</sub>Receptor Inverse AgonistRobert L. Hudkins, Michael Williams, Ming Tao et al.|Journal of Medicinal Chemistry|2011Cited by 68
CEP-26401 (Irdabisant), a Potent and Selective Histamine H3 Receptor Antagonist/Inverse Agonist with Cognition-Enhancing and Wake-Promoting ActivitiesRita Raddatz, Michael Williams, Siyuan Le et al.|Journal of Pharmacology and Experimental Therapeutics|2011Cited by 58
Mixed-Lineage Kinase 1 and Mixed-Lineage Kinase 3 Subtype-Selective Dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: Optimization, Mixed-Lineage Kinase 1 Crystallography, and Oral in Vivo Activity in 1-Methyl-4-phenyltetrahydropyridine ModelsRobert L. Hudkins, John P. Mallamo, Jean Husten et al.|Journal of Medicinal Chemistry|2008Cited by 43